openPR Logo
Press release

Investigation announced for Long-Term Investors in Ocugen, Inc. (NASDAQ: OCGN) shares

09-21-2021 06:31 PM CET | Business, Economy, Finances, Banking & Insurance

Press release from: Shareholders Foundation

An investigation on behalf of current long term investors in Ocugen, Inc. (NASDAQ: OCGN) shares.

An investigation on behalf of current long term investors in Ocugen, Inc. (NASDAQ: OCGN) shares.

An investigation was announced concerning potential breaches of fiduciary duties by certain directors of Ocugen, Inc.

Investors who are current long term investors in Ocugen, Inc. (NASDAQ: OCGN) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

The investigation by a law firm for current long term investors in NASDAQ: OCGN stocks follows a lawsuit filed against Ocugen, Inc. over alleged securities laws violations. The investigation on behalf of current long term investors in NASDAQ: OCGN stocks, concerns whether certain Ocugen directors are liable in connection with the allegations made in that lawsuit.

According to that complaint filed in the U.S. District Court for the Eastern District of Pennsylvania the plaintiff alleges that Ocugen, Inc made materially false and/or misleading statements and/or failed to disclose that the information submitted to the U.S. Food and Drug Administration ("FDA") was insufficient to support an Emergency Use Authorization ("EUA"), that Ocugen, Inc would not file an EUA with the FDA, and that as a result of the foregoing, the Company's financial statements, as well as Defendants' statements about Ocugen's business, operations, and prospects, were false and misleading and/or lacked a reasonable basis.

Those who purchased shares of Ocugen, Inc. (NASDAQ: OCGN) have certain options and should contact the Shareholders Foundation. Contact: Shareholders Foundation, Inc.

Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Investigation announced for Long-Term Investors in Ocugen, Inc. (NASDAQ: OCGN) shares here

News-ID: 2401411 • Views: 563

More Releases from Shareholders Foundation

Investigation announced for Investors in NASDAQ: CRMD shares over potential Wron …
An investigation was announced concerning potential breaches of fiduciary duties by certain directors and officers of CorMedix Inc.. Investors who are current long term investors in CorMedix Inc. (NASDAQ: CRMD) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm for current long term investors in NASDAQ: CRMD stocks follows a lawsuit filed against CorMedix Inc. over
Investigation announced for Investors in NYSE: OUST shares over possible Wrongdo …
An investigation on behalf of investors in shares of Ouster, Inc. (NYSE: OUST) was announced over potential breaches of fiduciary duties by certain officers and directors at Ouster, Inc. Investors who purchased shares of Ouster, Inc. (NYSE: OUST) have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm concerns whether certain Ouster, Inc. directors breached their fiduciary duties and
Investigation announced for Investors in Amplify Energy Corp. (NYSE: AMPY) over …
An investigation was announced over potential securities laws violations by Amplify Energy Corp. in connection with certain statements. Investors who purchased shares of Amplify Energy Corp. (NYSE: AMPY), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of Amplify Energy Corp. (NYSE: AMPY) concerning whether a series
Investigation announced for NYSE: TUYA shares over possible Wrongdoing at Tuya I …
An investigation on behalf of current long-term investors in shares of Tuya Inc. (NYSE: TUYA) was announced over potential breaches of fiduciary duties by certain officers and directors at Tuya Inc. Investors who purchased shares of Tuya Inc. (NYSE: TUYA) and currently hold any of those Tuya Inc. (NYSE: TUYA shares have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a

All 5 Releases


More Releases for Ocugen

COVID-19 Impact on Retinitis Pigmentosa Treatment & Management Market Overview a …
Retinitis Pigmentosa Treatment & Management Market is expected to grow significantly over next few years and generate considerable market for Retinitis Pigmentosa Treatment & Management. Market Report Expert has recently published a research report titled, “Retinitis Pigmentosa Treatment & Management Market Outlook and Statistics, 2020-2026". The report has been prepared by experienced and knowledgeable market analysts, researchers, market experts, and key option leaders within Retinitis Pigmentosa Treatment & Management market. It
Retinitis Pigmentosa (RP) Market 2025 : Ocugen, Inc., ReGenX Biosciences, LLC, S …
Global Retinitis Pigmentosa (RP) Market: Snapshot Retinitis pigmentosa, is a condition where patients typically loses ability to see at night in young years, side vision in middle age, and focal vision in later in his/her life due to relentless loss of cone photoreceptor cells. Proportions of retinal capacity, for example, the electroretinogram, demonstrate that photoreceptor capacity is decreased normally quite before symptomic night visual impairment, visual-field scotomas, or diminished visual sharpness
Retinitis Pigmentosa (RP) Market | Amarantus BioScience Holdings, Inc., Ocugen, …
Global Retinitis Pigmentosa (RP) Market: Snapshot Retinitis pigmentosa, in which patients usually lose night vision in teenage years, side vision in middle age, and central vision in later life because of steady loss of cone photoreceptor cells and rod. Measures of retinal function, such as the electroretinogram, indicate that photoreceptor function is reduced usually several years before visual-field scotomas, symptomic night blindness, or reduced visual acuity arise. Get Sample Copy of
Retinitis Pigmentosa (RP) Market | Amarantus BioScience Holdings, Inc., Ocugen, …
Global Retinitis Pigmentosa (RP) Market: Snapshot Retinitis pigmentosa, in which patients usually lose night vision in teenage years, side vision in middle age, and central vision in later life because of steady loss of cone photoreceptor cells and rod. Measures of retinal function, such as the electroretinogram, indicate that photoreceptor function is reduced usually several years before visual-field scotomas, symptomic night blindness, or reduced visual acuity arise. Get Brochure of the
Choroidal Neovascularization Therapeutics Pipeline Analysis 2018 | Graybug Visio …
Choroidal neovascularization is a type of medical condition in which new blood vessels are formed from choroid and extend into the subretinal space, or subretinal pigment epithelium, or a combination of both. Download the sample report @ https://www.pharmaproff.com/request-sample/1122 The disease can be symptomatized by a painless loss of vision, paracentral or central scotoma, and metamorphopsia. Choroidal neovascularization can be diagnosed by indocyanine green angiography, spectral domain optical coherence tomography, and fluorescein angiography.
Retinitis Pigmentosa (RP) Market Estimated to Flourish at by 2025 | Amarantus Bi …
Global Retinitis Pigmentosa (RP) Market: Snapshot Retinitis pigmentosa, in which patients usually lose night vision in teenage years, side vision in middle age, and central vision in later life because of steady loss of cone photoreceptor cells and rod. Measures of retinal function, such as the electroretinogram, indicate that photoreceptor function is reduced usually several years before visual-field scotomas, symptomic night blindness, or reduced visual acuity arise. Get Brochure of the